Clinical Trials
13 trialsNCT04701476 2026-04-16
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Teclison Ltd.
Phase 2 Recruiting
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT07343791 2026-01-15
Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.
Jinling Hospital, China
Phase EARLY_PHASE1 Recruiting
NCT07213570 2025-12-17
STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer
National Cancer Institute, Naples
Phase 2 Recruiting
NCT06887218 2025-08-27
5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
The Methodist Hospital Research Institute
Phase 2 Recruiting
NCT06992648 2025-05-28
REGTAS-2
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3 Recruiting
NCT06949982 2025-05-04
x-МАР
Pavlov First Saint Petersburg State Medical University
Phase 2 Recruiting
NCT06456515 2025-02-17
Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC
The First People's Hospital of Changzhou
Phase NA Recruiting
NCT06425133 2024-12-24
CARE
Centre Hospitalier Universitaire de Besancon
Phase 2 Recruiting
NCT05462613 2024-12-20
REPROGRAM-02
Centre Hospitalier Universitaire de Besancon
Phase 2/3 Recruiting
NCT06543836 2024-08-09
ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT05985109 2023-10-26
KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer
Peking University Cancer Hospital & Institute
Phase 2 Recruiting
NCT05970705 2023-08-01
Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC
Fudan University
Phase 2 Recruiting